Every 8-K that Qualigen Therapeutics Inc (QLGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow QLGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QLGN filings page.
AIxCrypto Holdings reported major leadership changes and a strategic exit from its legacy biotechnology business. Co-Chief Executive Officer and director Kevin Richardson II, Chief Financial Officer and director Koti Meka, and President Campbell Becher resigned their roles, with Mr. Meka remaining CFO until June 20, 2026.
The Board appointed director Jie (Jay) Sheng as President immediately and as Chief Financial Officer effective June 21, 2026. His offer includes a $400,000 base salary, up to $200,000 annual bonus, and proposed equity awards subject to Board approval and share availability. Jerry Wang and Chen Shi were also appointed as directors, with Mr. Shi deemed an independent director and expected to chair the Audit Committee.
The Board approved a structured wind-down of the company’s legacy biotechnology segment after reviewing strategic alternatives. The company is evaluating potential charges, asset impairments, and other costs from this discontinuation and plans to provide further details in its next periodic SEC report.
AIxCrypto Holdings, Inc. entered into a material agreement to sell its loan and related rights tied to Marizyme, Inc. to CABG ACQUISITION CORP. The Note Package includes an amended secured promissory note with outstanding principal of about $4,771,142 at 18% interest, a $1,750,000 co-development note, and a security interest in substantially all Marizyme assets.
In return, AIxCrypto will receive $100,000 in cash, royalty payments equal to 10% of Net Revenue on cumulative Net Revenue above $20,000,000, and a 4.99% membership interest in the Buyer. AIxCrypto also gains customary preemptive and registration rights. The closing will occur on a mutually agreed date, with either party able to terminate if it has not closed within 90 days.
AIxCrypto Holdings, Inc. describes multiple amended agreements tied to its entrusted investment in Faraday Future Intelligent Electric Inc. (FFAI). The entrusted investment agreement with GOLD KING ARTHUR HOLDING LIMITED and Song Wang was expanded so “FFAI Shares” now cover FFAI preferred stock, loans, debt instruments and convertible notes.
GKA and FFAI amended their securities purchase agreement, raising the subscription amount to $12 million, with $500,000 for FFAI Class A common shares and $11.5 million for Series C Convertible Preferred Stock at a $0.26 per share reference price. FFAI also issued a warrant for 1,000,000 Class A shares and created 11,502 shares of Series C Convertible Preferred Stock, convertible using a stated value of $1,000 per share and a conversion price of $0.26, with an alternative conversion price mechanism.
In connection with these transactions, FFAI entered into a $2,000,000 loan agreement with GKA at 10% interest, funded by AIxCrypto under the entrusted structure, which was later terminated when its principal and interest were applied toward the revised subscription amount.
AIxCrypto Holdings reported full-year 2025 results and detailed its transformation from a biopharma business into an AI and blockchain digital infrastructure company. Fiscal 2025 focused on repositioning, including a $41.0 million PIPE financing, a rebrand, and a new leadership team.
As of December 31, 2025, the company reported approximately $31 million in total assets, including about $19 million in cash and cash equivalents, against roughly $3 million in total liabilities, for stockholders’ equity of about $28 million. Aggregate gross financing proceeds during 2025 were approximately $42 million, and net cash used in operating activities was $6,951,458, compared with $6,327,503 in 2024.
AIxCrypto is building an AI Agent and Embodied AI blockchain ecosystem and advancing a Real World Asset tokenization business. It deployed $10 million into FFAI stock in February 2026 as a potential underlying asset and is targeting about 100,000 monthly active users across its ecosystem by year-end 2026, excluding AIxC Hub.
AIxCrypto Holdings, Inc. filed an update describing a new strategic focus and product progress rather than financial results. The company’s AIxC Hub platform has entered Season 2, adding new engagement mechanics and Tenki-based interactive modules to deepen AI agent-driven experiences.
Management, led by Co-CEO Jerry Wang, plans to concentrate resources on Real-World Asset (RWA) and Embodied AI (EAI) initiatives, including intelligent electric vehicles and AI robotics, while phasing out BesTrade AI Agent and Digital Asset AI Management modules to sharpen operational focus. The press release also highlights growing community traction, with the official X account reaching 53,417 followers, a 94% increase in engagement rates, and total impressions approaching 600,000, and reiterates extensive forward-looking statement cautions and risk factors.
AIxCrypto Holdings, Inc. detailed several new leadership and advisory arrangements. The company entered an Advisor Agreement with Yueting (YT) Jia, effective October 2, 2025, with a fixed annual fee of $500,000, a target performance fee of $500,000 per year, a $300,000 engagement fee, and anticipated annual RSU and PSU grants each targeted at $1.5 million.
The company also finalized a Co-CEO Employment Agreement for Jiawei Wang with a $300,000 base salary, a $200,000 cash advance vesting over 36 months, and severance and equity-vesting protections upon certain terminations or change of control. A Stay Letter Agreement and amendment for Co-CEO Kevin A. Richardson II provide a lump-sum payment equal to his $234,000 base salary upon certain terminations and add a retroactive $4,500 monthly fee. In addition, Chief Financial Officer Koti Meka, serving in a part-time fractional role, receives a $150,000 base salary, an annual bonus opportunity up to $70,000, and potential annual equity awards valued at $200,000.
AIxCrypto Holdings, Inc. (QLGN) reported that Nasdaq notified the company it had failed to comply with Listing Rule 5635(b), which requires shareholder approval before an issuance of securities that results in a change of control. The issue related to a $41,000,000 PIPE financing that closed on September 29, 2025, involving 337,432 shares of common stock and 17,783 shares of Series B Convertible Preferred Stock sold to investors including Faraday Future Intelligent Electric Inc.
Nasdaq determined that this financing, together with significant board and management changes involving Faraday-affiliated individuals, constituted a change of control without prior shareholder approval. The company later obtained majority shareholder approval, and Nasdaq informed it that the deficiency was remediated and the matter closed, with no impact on the current listing of its common stock. Separately, on November 19, 2025, Nasdaq confirmed the company is in compliance with Listing Rule 5550(b)(1) on stockholders’ equity, but the company will remain under a one-year Panel Monitor period.
AIxCrypto Holdings, Inc., formerly operating under the Nasdaq ticker QLGN, reported that it has launched a new corporate name and trading symbol “AIXC”. The company marked this rebranding with a presentation at Nasdaq headquarters, where it highlighted the new name and elements of an updated business plan focused on its AI and crypto-related strategy.
The company also issued a press release on November 20, 2025, announcing the rebranding and updated business plan, which is included as an exhibit to this report. A video link to the Nasdaq presentation was provided for investors and the public to review the company’s new positioning and strategic direction.
Qualigen Therapeutics, Inc. announced several board changes effective November 17, 2025. The Nominating and Governance Committee appointed Koti Meka, the Company’s Chief Financial Officer who also serves as CFO of Faraday Future Intelligent Electric Inc., as an Executive Director. The Committee also named Jie Sheng, Head of Operations & Finance Director of FF Global Partners LLC, as Chairman of the Board of Directors.
On the same date, Chad Chen, already a board member, was appointed to the Board’s Audit Committee. The Company states there are no compensation arrangements, plans, or agreements entered into with the newly appointed board members. Directors Graydon Bensler and Braeden Lichti resigned from the Board, and their resignations were noted as not resulting from any disagreements regarding the Company’s operations, policies, or practices.
Qualigen Therapeutics, Inc. reported that it has amended its charter in Delaware to change its corporate name to AIxCrypto Holdings, Inc. The company expects its common stock to stop trading under the ticker “QLGN” and begin trading on the Nasdaq Capital Market under the new symbol “AIXC” as promptly as possible. The name change does not alter the rights of existing stockholders.
At a 2025 special meeting, holders of approximately 60.17% of the voting stock were present, and a majority approved several key proposals. Stockholders approved a Subscription Agreement covering the private placement of 337,432 common shares and 39,943 shares of Series B Convertible Preferred Stock, the issuance of common shares upon conversion of that preferred stock in excess of a 19.99% share exchange cap, the company’s 2025 Equity Incentive Plan, and the ability to adjourn or postpone the meeting.
Qualigen Therapeutics reports several governance and audit changes. Its prior auditor, WithumSmith+Brown, resigned effective October 1, 2025, ending engagements for the September 30, 2025 quarterly review and the December 31, 2025 year-end audit. Withum’s report on the year ended December 31, 2024 included an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern, but otherwise was not adverse or qualified, and the company states there were no disagreements or other reportable events beyond previously disclosed material weaknesses in internal control over financial reporting.
The Audit Committee approved Macias Gini & O’Connell LLP as new independent auditor for the 2025 year-end audit and specified interim reviews through September 30, 2026, subject to client acceptance procedures. Effective October 2, 2025, the company appointed Jiawei Wang as Co‑Chief Executive Officer and Koti Meka as Chief Financial Officer, and added three new directors, who also joined key board committees. Three existing directors resigned in connection with a recent private placement, with the company stating these departures were not due to disagreements.
Qualigen Therapeutics (QLGN) closed a $41,000,000 private placement on September 29, 2025, selling 337,432 shares of common stock at $2.246 and 17,783 shares of Series B Convertible Preferred Stock at a $1,000 stated value. The Series B converts into common at a $2.246 conversion price after Stockholder Approval under Nasdaq Rule 5635, with allocations capped at 19.99% ownership per investor at closing.
The company plans to use up to $6,800,000 of net cash proceeds to pay existing debt and fund current operations, with the balance of cash proceeds and contributed currency for establishing cryptocurrency treasury operations. Qualigen agreed to file a resale registration within 45 days of closing and target effectiveness 45 days thereafter (or 60 days if fully reviewed). Univest Securities will receive a 5.5% cash fee, warrants equal to 6% of securities sold at a $2.47 exercise price, and up to $150,000 in expenses. The Lead Investor, Faraday Future Intelligent Electric Inc., secured board designation rights; board changes include appointing Jiawei Wang as Co‑CEO and Koti Meka as CFO, alongside three director resignations.
Qualigen Therapeutics, Inc. reported that its Board of Directors appointed Kevin Chen as an independent director, effective September 26, 2025. As of this appointment, he has not yet been assigned to any Board committees. Chen is currently Chief Economist and CIO of Horizon Financial and serves on several public company boards, including CurrenC Group, Australian Oilseeds Investments, Scage Future and Capitan Investment Ltd. His background includes senior investment roles at Credit Agricole/Amundi Asset Management and Morgan Stanley, as well as academic positions at New York University and other institutions.
Qualigen Therapeutics entered into a private placement on September 19, 2025, under which investors, led by Faraday Future Intelligent Electric Inc., agreed to purchase $41,000,000 of common stock and new Series B convertible preferred stock. Common shares are priced at $2.246 and Series B shares at $1,000 each, with Series B convertible into common at a $2.246 conversion price after required stockholder approval under Nasdaq Rule 5635. The company plans to use up to $6,800,000 of net cash proceeds to pay existing debt and fund current operations, with remaining cash and contributed currency earmarked for cryptocurrency treasury operations.
Univest Securities will receive a 5.5% cash fee on gross proceeds, warrants equal to 6% of securities sold exercisable at $2.47 per share, and up to $150,000 in expense reimbursement. A Lead Investor Agreement gives Faraday Future board representation rights while it owns at least 5% of outstanding common stock, including the appointment of Jiawei Wang as Co‑CEO and Koti Meka as CFO. An advisory firm will receive approximately 60,257 common shares, described as 5% of outstanding common stock following the closing.
Qualigen Therapeutics, Inc. filed a current report describing an amendment to its secured borrowing arrangement with Marizyme, Inc. On September 15, 2025, the company entered into Amendment No. 1 to its Amended and Restated Secured Demand Promissory Note dated August 21, 2025.
The amendment corrects the note’s maturity date to August 21, 2026, increases the advance and principal amount by $75,000, and results in a revised outstanding principal balance of $4,526,462.18. The additional advance accrues interest at the same rate set in the existing note, and the company’s obligations remain secured under the existing Security Agreement. The amendment also triggers disclosure of a direct financial obligation under the relevant reporting item.
Qualigen Therapeutics reported that a Nasdaq Hearings Panel has issued a decision on its continued listing. The company previously received an exception to meet Nasdaq’s stockholders’ equity requirement of $2.5 million by July 28, 2025, but its June 30, 2025 Form 10-Q showed stockholders’ equity of approximately negative $1.6 million, so it did not meet the deadline.
The company subsequently closed a private placement of Series A-3 Preferred Stock with net proceeds of about $4.3 million and amended a promissory note with Marizyme, Inc., which increased stockholders’ equity by more than $600,000. The Panel stated that these actions cannot be used to show compliance as of July 28 but granted a final exception to demonstrate compliance in the Form 10-Q for the quarter ending September 30, 2025, which must be filed no later than November 15, 2025. If compliance is not demonstrated then, no additional time will be granted. The company has regained compliance with Nasdaq’s periodic filing rule.
Qualigen Therapeutics has expanded and restructured its lending arrangement with Marizyme through an Amended and Restated Secured Demand Promissory Note with a principal balance of $4,451,462.18. The note carries 18% annual interest, with all principal and interest due in a single balloon payment on August 21, 2026, and the rate rising by 5% upon default.
Qualigen agreed to conditionally forbear from demanding payment for 365 days unless Marizyme defaults, and obtained a security interest in substantially all of Marizyme’s assets. The company also highlights a recent private placement of 4,500 shares of Series A-3 Preferred Stock for approximately $4.5 million in gross proceeds, resulting in net proceeds of $4,257,937.50, and states it believes total shareholders’ equity now exceeds $2.5 million.
On 23 Jul 2025 Qualigen Therapeutics (Nasdaq:QLGN) received a Nasdaq notice that its stockholders’ equity, as reported in the 31 Mar 2025 Form 10-Q, fell below the $2.5 million minimum required by Listing Rule 5550(b)(1). On 24 Jul 2025 Nasdaq’s Office of the General Counsel granted an extension after reviewing the company’s compliance plan and a pro-forma balance sheet reflecting a $4.5 million private placement of Series A-3 preferred stock, which would raise equity above the threshold.
Nasdaq accepted the plan, giving the company up to 12 months to evidence sustained compliance. Management is working to maintain the Nasdaq Capital Market listing but offers no assurance of success. Supporting materials include a press release dated 28 Jul 2025 (Ex. 99.1) and an unaudited pro-forma balance sheet (Ex. 99.2).
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) filed a Form 8-K announcing a board-level governance change effective June 20 2025. Independent director Robert B. Lim was appointed Chair of the Audit Committee, succeeding Graydon Bensler, who will remain a committee member. The board affirmed that Lim meets Nasdaq Rule 5605 and SEC Rule 10A-3 independence criteria and is deemed an “audit committee financial expert” under Regulation S-K Item 407(d)(5). The filing states there are no related-party transactions or special arrangements connected to Lim’s elevation. No other management changes, financial results, or transactions were disclosed.